Takeda Pharmaceutical (NYSE:TAK) Releases Fiscal 2022 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK- Get a rating) updated its earnings guidance for fiscal 2022 on Thursday. The company provided EPS guidance of $3.74 to $3.74 for the period. The company released revenue forecasts of $28.49 billion to $28.49 billion.

Changes to analyst ratings

TAK has been the subject of a number of recent research reports. Cowen upgraded Takeda Pharmaceutical from a market performance rating to an outperformance rating in a Tuesday, July 19 research report. Cowen upgraded Takeda Pharmaceutical shares from a market performer rating to an outperformer rating and raised its price target for the stock from $21.00 to $24.00 in a Tuesday 19 research report. July. Finally, Jefferies Financial Group downgraded shares of Takeda Pharmaceutical from a buy rating to a hold rating in a Friday, July 29 research report. Three analysts gave the stock a hold rating and two gave the stock a buy rating. According to data from MarketBeat.com, Takeda Pharmaceutical has an average rating of Hold and an average target price of $24.00.

Takeda Pharmaceutical price performance

Shares of NYSE:TAK traded at $0.02 during Thursday’s midday session, hitting $13.91. The stock had a trading volume of 43,150 shares, compared to an average volume of 2,739,679. The company has a current ratio of 1.18, a quick ratio of 0.75 and a leverage ratio of 0, 68. Takeda Pharmaceutical has a 1-year low of $13.05 and a 1-year high of $17.31. The company’s 50-day moving average price is $14.08 and its 200-day moving average price is $14.50. The company has a market cap of $44.02 billion, a P/E ratio of 26.21, a price-to-earnings growth ratio of 0.56, and a beta of 0.70.

Takeda Pharmaceutical (NYSE:TAK- Get a rating) last announced its quarterly results on Wednesday, May 11. The company reported earnings per share of $0.38 for the quarter. The company posted revenue of $7.19 billion for the quarter. Takeda Pharmaceutical had a net margin of 5.43% and a return on equity of 12.41%. Research analysts expect Takeda Pharmaceutical to post EPS of 2.25 for the current fiscal year.

Takeda Pharmaceutical Institutional Trading

A number of institutional investors have recently bought and sold shares of TAK. Beacon Pointe Advisors LLC increased its position in Takeda Pharmaceutical shares by 11.2% during the first quarter. Beacon Pointe Advisors LLC now owns 11,861 shares of the company worth $170,000 after purchasing an additional 1,190 shares in the last quarter. HighTower Advisors LLC increased its stake in Takeda Pharmaceutical by 7.5% in Q1. HighTower Advisors LLC now owns 28,326 shares of the company worth $404,000 after purchasing an additional 1,983 shares during the period. Brown Brothers Harriman & Co. bought a new position in shares of Takeda Pharmaceutical during the first quarter worth $105,000. American Century Companies Inc. increased its stake in Takeda Pharmaceutical by 14.5% in the 1st quarter. American Century Companies Inc. now owns 70,780 shares of the company worth $1,014,000 after acquiring 8,941 additional shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in Takeda Pharmaceutical in the first quarter worth approximately $156,000. 2.40% of the shares are currently held by institutional investors.

Takeda Pharmaceutical Company Profile

(Get a rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing and licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, the rest of Asia and internationally. It offers pharmaceutical products in the fields of gastroenterology, rare diseases, plasma-derived therapies, oncology and neurosciences.

Featured articles

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Takeda Pharmaceutical right now?

Before you consider Takeda Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Takeda Pharmaceutical wasn’t on the list.

Although Takeda Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here